Boardroom Alpha
Boardroom Alpha
CHRS · Additional Proxy Materials (DEFA14A) · Filed May 5, 2026

Coherus Oncology Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
May 5, 2026
Ticker
CHRS
Accession
0001104659-26-055695
Boardroom Alpha · Filing insights

Coherus Oncology urges voting on proxy proposals, including repricing employee stock options; pass requires majority FOR votes.

About Coherus Oncology Inc
Market cap
$235M
1Y TSR
+113.6%
3Y TSR
−28.7%
Board grade
C-
Sector
Healthcare
CEO
Dennis M Lanfear
Last annual meeting: May 27, 2026 · View full Coherus Oncology Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

Filed by the Registrant x

Filed by a party other than the Registrant ¨

 

Check the appropriate box:

 

¨ Preliminary Proxy Statement
¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨ Definitive Proxy Statement
x Definitive Additional Materials
¨ Soliciting Material under §240.14a-12

 

Coherus Oncology, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

x No fee required.
¨ Fee paid previously with preliminary materials.
¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 

 

 

The following communication was made to Coherus Oncology, Inc. (the “Company”) employees:

 

To: All Employees Email

 

From: Rebecca Sunshine

 

May 5, 2026

 

Subject: Annual Shareholder Meeting - Please vote!

 

To All Coherus Employees,

 

I am sending a reminder email to please vote for the proposals in our Proxy before the Annual Shareholder Meeting on May 27, 2026, at 1:30pm PST. There are several proposals in the Proxy for shareholders to vote on, including a proposal to reprice employee stock options which have strike prices that are $5 and above down to the closing price on the date of the meeting. The proposal requires that a majority of votes cast “FOR” to pass. We encourage you to vote your shares when you receive the proxy. For anyone who has not received the proxy via email, you can call our Proxy Solicitor – Christopher Rice at (203) 561-6945, and he can take your vote over the phone.

 

Thank you, Rebecca

 

Rebecca Sunshine

 

Chief Human Resources Officer

 

TEL [***]

CELL [***]

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Coherus Oncology Inc (CHRS)

Reference

Frequently asked questions

When did Coherus Oncology Inc file this DEFA14A?
Coherus Oncology Inc (CHRS) filed this Additional Proxy Materials (DEFA14A) with the SEC on May 5, 2026. The accession number assigned by EDGAR is 0001104659-26-055695.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Coherus Oncology urges voting on proxy proposals, including repricing employee stock options; pass requires majority FOR votes. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Coherus Oncology Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Coherus Oncology Inc has filed under CIK 1512762, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer